KCM
ENGN icon

Kennedy Capital Management’s enGene Therapeutics ENGN Stock Holding History

Kennedy Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$465K Sell
268,735
-157,046
-37% -$640K 0.01% 523
2026
Q1 		$2.9M Buy
425,781
+349,016
+455% +$3.11M 0.06% 375
2025
Q4 		$693K Buy
+76,765
New +$615K 0.01% 504

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Kennedy Capital Management's ENGN Position: Q2 2026 in Review

Kennedy Capital Management reduced its enGene Therapeutics (ENGN) stake by 37% in Q2 2026, selling an estimated $640K and leaving 268,735 shares worth $465K. The position accounts for 0.01% of the portfolio, ranked #523.

Kennedy Capital Management first reported a position in ENGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.9M in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

  • Kennedy Capital Management held 268,735 shares of enGene Therapeutics worth $465K as of Q2 2026.
  • Kennedy Capital Management sold 157,046 enGene Therapeutics shares in Q2 2026, an estimated $640K.
  • enGene Therapeutics made up 0.01% of Kennedy Capital Management's portfolio in Q2 2026, its #523 holding.
  • Kennedy Capital Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Kennedy Capital Management's enGene Therapeutics position peaked at $2.9M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.